0001213900-24-089358.txt : 20241021 0001213900-24-089358.hdr.sgml : 20241021 20241021171931 ACCESSION NUMBER: 0001213900-24-089358 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20241021 DATE AS OF CHANGE: 20241021 EFFECTIVENESS DATE: 20241021 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NLS Pharmaceutics Ltd. CENTRAL INDEX KEY: 0001783036 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-527384 FILM NUMBER: 241384203 BUSINESS ADDRESS: STREET 1: THE CIRCLE 6 STREET 2: 8058 CITY: ZURICH STATE: V8 ZIP: CH-6370 BUSINESS PHONE: 41-41-618-80-00 MAIL ADDRESS: STREET 1: THE CIRCLE 6 STREET 2: 8058 CITY: ZURICH STATE: V8 ZIP: CH-6370 D 1 primary_doc.xml X0708 D LIVE 0001783036 NLS Pharmaceutics Ltd. THE CIRCLE 6 ZURICH V8 SWITZERLAND CH-8058 +41.44.512.2150 SWITZERLAND None None Other Limited Company true Alexander Zwyer The Circle 6 Zurich V8 SWITZERLAND CH-8058 Executive Officer Director Chief Executive Officer Ronald Hafner The Circle 6 Zurich V8 SWITZERLAND CH-8058 Director Elena Thyen-Pighin The Circle 6 Zurich V8 SWITZERLAND CH-8058 Executive Officer Chief Financial Officer Florence Allouche Aknin The Circle 6 Zurich V8 SWITZERLAND CH-8058 Director Claudio L.A. Bassetti The Circle 6 Zurich V8 SWITZERLAND CH-8058 Director Gian-Marco Rinaldi The Circle 6 Zurich V8 SWITZERLAND CH-8058 Director Audrey Greenberg The Circle 6 Zurich V8 SWITZERLAND CH-8058 Director Pharmaceuticals Decline to Disclose 06b false 2024-10-11 false true true true false 0 7200000 7200000 0 Represents total gross proceeds received by the company in connection with a concurrent private placement of common shares, concurrent private placement of warrants to purchase common shares and concurrent private placement of preferred shares. false 6 0 15000 true The Company agreed to pay a finder's fee, either in cash or common shares, to the finder for facilitating a $300,000 investment from a specific investor. 0 General corporate purposes and working capital. false NLS Pharmaceutics Ltd. /s/ Alexander Zwyer Alexander Zwyer Chief Executive Officer 2024-10-21